Madison Realty Capital Provides $35 Million Mezzanine Loan for 611 West 56th Street Condominium Development in Hell's Kitchen
Part of Overall $155 Million Financing Package Provided by MRC and Apollo Global Management for Planned 35 Story Condo Tower at 56th Street and Eleventh Avenue
First New York City Project Designed by Renowned Architect Álvaro Siza
NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- Madison Realty Capital (MRC) provided a $35 million mezzanine loan to co-developers Sumaida + Khurana and LENY for a new condominium tower located at 611 West 56th Street in the Hell's Kitchen neighborhood of Manhattan. The funding is part of a $155 million construction financing package for the project provided by MRC and an investment fund managed by Apollo Global Management.
Located in the evolving Hudson West neighborhood, 611 West 56th Street will stand 35 stories in height, encompass 163,329 square feet and feature 83 residences, ranging from one-bedrooms to expansive penthouses. The condominium will also feature a significant amount of outdoor space, including a landscaped roof garden and sun deck, as well as numerous private terraces for the residents. Residents will also have access to a state of the art fitness center, children's playroom and an entertaining space to host private events.
"We're pleased to play an important role in providing the financing solution for this high-profile development in Manhattan," said Josh Zegen, Co-Founder and Managing Principal of MRC. "We continue to be successful in meeting the needs of borrowers at all stages of the development process, from predevelopment to construction to sellout or stabilization. In this case, the sponsor has invested substantial equity into the project, and we're involved at an attractive basis in a well-located project with an experienced team behind it."
The building is being designed by Pritzker Prize-winning architect Álvaro Siza and represents his first foray into the U.S. market, a major milestone for the renowned Portuguese architect. Siza is one of the world's most celebrated and decorated architects, designing such iconic structures like the Boa Nova Tea House and Piscinas de Marés in Portugal as well as recently commissioned projects in China, South Korea, Spain, Argentina, Brazil and the Netherlands. IA award-winning architects, Michael Gabellini and Kimberly Sheppard will collaborate with Siza on the 611 West 56th Street building's interiors and SLCE Architects will serve as the Architect of Record.
The 611 West 56th Street development team has significant previous experience in ground-up residential projects. Sumaida + Khurana is a New York-based development firm focused on developing seminal buildings throughout the city and commissioning the world's most renowned, contemporary architects to design them. One of the firm's notable projects, 152 Elizabeth, is rapidly approaching completion and is the first building in New York by Japanese master architect Tadao Ando.
New York-based firm LENY has been responsible for the development of millions of square feet of residential projects around the world. The firm specializes in bringing to market high-end condominium buildings in premium locations and is currently focusing its efforts in New York City. 611 West 56th Street will be one of four projects the firm is developing, including 534 West 29th Street and the Berry Portfolio in Williamsburg as well as serving as one of the equity partners at 277 Fifth Avenue. LENY is collectively developing over half a million square feet in New York City.
Adi Chugh of Maverick Capital Partners arranged the financing in the transaction. Sales at 611 West 56th Street are slated to begin in Spring 2019 and Leonard Steinberg, Debra LaChance, and Justin D'Adamo at Compass will lead the marketing efforts.
About Madison Realty Capital (MRC)
MRC is a New York-based real estate investment firm that pursues real estate equity and debt investments in the middle market. Founded in 2004, MRC has invested in approximately $7.0 billion of transactions in the multifamily, retail, office, industrial and hotel sectors.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Madison Realty Capital via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Manufacturing Leadership Forum Will Highlight Enabling Industry 4.0 with Analytics25.9.2018 15:06 | Pressemelding
Upcoming Dates in Houston, Texas and Antwerp, Belgium PORTLAND, Ore., Sept. 25, 2018 (GLOBE NEWSWIRE) -- New dates for The Manufacturing Leadership Forum were announced today including Houston, Texas, US on October 9, 2018 at the Petroleum Club of Houston and on November 28, 2018 in Antwerp, Belgium at the Lindner WTC Hotel & City Lounge. The events are sponsored by Northwest Analytics, a leading provider of manufacturing intelligence and SPC software solutions for manufacturers. This premier manufacturing analytics educational event focuses on enabling Industry 4.0 programs with manufacturing analytics. The Forums will feature keynotes and case-study presentations from globally-recognized leaders in the application of manufacturing analytics. In its fourth year, The Manufacturing Leadership Forum will open with a keynote from analytics visionary, Dr. Lloyd Colegrove, Director of Data Services & Fundamental Problem Solving at The Dow Chemical Company. “The Manufacturing Leadership Foru
Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-10125.9.2018 14:00 | Pressemelding
Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer Phase 3 trial in treatment-naïve EGFR mutation-positive NSCLC patients targeted to commence in 2019 NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that positive preliminary safety and efficacy data from an ongoing Phase 1/2 clinical trial of CK-101 were presented yesterday in an oral presentation at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer in Toronto. The oral presentation included further details on, and updates from, the dataset announced previously. CK-101 is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being evaluated in advanced non
SpeeDx Begins Multisite U.S. Clinical Trials of ResistancePlus® MG Test25.9.2018 14:00 | Pressemelding
Test supports international guidelines for treating antibiotic resistant STI SYDNEY, Australia, Sept. 25, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. today announced the start of patient testing in their multisite U.S.-based clinical trials for ResistancePlus® MG (not available for sale in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma genitalium, also known as Mgen or MG, along with genetic markers linked to antibiotic resistance. In recent years, Mgen prevalence has increased globally and developed high rates of resistance to the common antibiotic treatment, azithromycin. "This test is an exciting new development that will increase the precision of patient care for patients impacted by Mycoplasma genitalium - a common sexually transmitted infection with limited treatment options,” notes Dr Maria Trent, Professor of Pediatrics and Public Health at Johns Hopkins Medicine. The SpeeDx ResistancePlus MG test is in use in laboratories acr
Novavax Initiates Phase 2 Clinical Trial of NanoFlu™ in Older Adults25.9.2018 13:00 | Pressemelding
First participants enrolled in Phase 2 clinical trial of quadrivalent NanoFlu formulations Top-line immunogenicity and safety data expected in the first quarter of 2019 Phase 2 results will support meeting with the U.S. Food and Drug Administration (FDA) and Phase 3 clinical trial design GAITHERSBURG, Md., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced the initiation of a Phase 2 dose and formulation confirmation clinical trial in older adults of NanoFlu, its nanoparticle seasonal influenza vaccine candidate. “Initiating this Phase 2 clinical trial of NanoFlu is an important milestone for Novavax,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “With top-line results expected in the first quarter of 2019, we plan to discuss these data with the FDA at an ‘End of Phase 2’ meeting and to agree on the appropriate Phase 3 clinical trial design to support licensure via accelerated approval. We continue to believe NanoFlu is a differen
CGAP Launches Photo and Video Contest Theme for 2018: Financial Inclusion in Africa25.9.2018 13:00 | Pressemelding
This year's CGAP contest is the first ever to accept short video entries WASHINGTON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- The Consultative Group to Assist the Poor’s (CGAP) 13th annual photo contest, launched today, is seeking striking images on financial inclusion in Africa. For the first time, short video submissions on Africa also will be accepted. Entries may be submitted through December 14, 2018. Each contestant may submit up to 20 photos or videos to compete for the Grand Prize worth US$ 2,000. This year CGAP is looking for original and compelling photographs and short videos that tell the story of how financial services empower poor people and communities in Africa. The region is a center for financial innovation -- home to M-Pesa, the mobile money service launched a decade ago now replicated across markets worldwide; host to vibrant FinTech and e-commerce companies; and to a growing off-grid sector that leverages digital finance. Together these innovators contribute toward lifti
Kick-starting health in the workplace25.9.2018 10:00 | Pressemelding
Over 800 organizations step, bike, swim and yoga their way to better health and wellbeing as the May 2018 Virgin Pulse Global Challenge Concludes ZURICH, Switzerland, Sept. 25, 2018 (GLOBE NEWSWIRE) -- On August 30th more than 270,000 people, across 144 countries, completed Virgin Pulse’s 100-day Global Challenge, moving them towards a more active, healthy and productive lifestyle. With this achievement, Virgin Pulse, an international leader in employee health and wellbeing, once again proves it’s helping to improve employee lives for good. The company’s Global Challenge event encourages exercise, mindfulness and healthy habits at work, leading to a happier culture and reduced costs to the organization. “Through increased awareness, education and motivation, employees master long-term, sustainable habits allowing them to arrive at work feeling more engaged, productive and equipped for peak performance,” says David Osborne, Chief Executive Officer of Virgin Pulse. “The follow-on effects
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom